Request Samples
Patient Savings
Request a Rep

Real QULIPTA patient.

Powerful
Reductions

Jump to Section

EPISODIC MIGRAINE

Powerful migraine day reductions that help give patients more zero-migraine days

POWER

Primary endpoint: Mean MMD reduction across 12 weeks

54%

MMD reduction across 12 weeks with QULIPTA® 60 mg (4.2 fewer MMD from 7.8 baseline) (n=222; P<0.001) vs 33% with placebo (2.5 fewer MMD from 7.5 baseline) (n=214)1

  • QULIPTA 30 mg: 49% MMD reduction (3.9 fewer MMD from 7.9 baseline) (n=223; P<0.001)1
  • QULIPTA 10 mg: 49% MMD reduction (3.7 fewer MMD from 7.5 baseline) (n=214; P<0.001)1

MMD=Monthly Migraine Days.

Response rates

50%-100% 50%-100%
100% 100%

Secondary endpoint: Percentage of patients who achieved ≥50% MMD reduction across 12 weeks1

WEEKS 1-12 61% (n=222; P<0.001) vs 29% with placebo (n=214)1

Similar 12-week average results were seen with other doses1:

  • 59% for QULIPTA 30 mg (n=223; P<0.001)
  • 56% for QULIPTA 10 mg (n=214; P<0.001)

Additional endpoint: Percentage of patients who achieved ≥50% MMD reduction in Weeks 1-4, 5-8, and 9-124

Graph showing 12-week 50-100% response rate migraine reduction for episodic migraine. Weeks 1-4: 61% saw reductions with Qulipta 60 mg (n=221) vs placebo (n=212). Weeks 5-8 66% saw reductions with Qulipta 60 mg (n=207) vs placebo (n=204). Weeks 9-12 71% saw reductions with Qulipta 60 mg (n=195) vs placebo (n=196).

LIMITATIONS: The additional endpoints were prespecified, non-ranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

Kelsi
Real QULIPTA patient.

Read her story
and others

Additional endpoint: Percentage of patients who achieved 100% MMD reduction across 12 weeks4

WEEKS 1-12 8% (n=222) vs 1% with placebo (n=214)2

Similar 12-week average results were seen with other doses2:

  • 5% for QULIPTA 30 mg (n=223)
  • 8% for QULIPTA 10 mg (n=214)

Additional endpoint: Percentage of patients who achieved 100% MMD reduction in Weeks 1-4, 5-8, and 9-124

Graph showing 12-week 100% response rate migraine reduction for episodic migraine. Weeks 1-4: 19% saw reductions with Qulipta 60 mg (n=221) vs placebo (n=212). Weeks 5-8 24% saw reductions with Qulipta 60 mg (n=207) vs placebo (n=204). Weeks 9-12 28% saw reductions with Qulipta 60 mg (n=195) vs placebo (n=196).

LIMITATIONS: The additional endpoints were prespecified, non-ranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

Kelsi
Real QULIPTA patient.

Read her story
and others

Reductions in migraine days and improvement in function at Week 1

MIGRAINE DAY REDUCTIONS

Additional endpoint: Change from baseline in weekly migraine days (WMD) at Week 1

Down Arrow

53%
MIGRAINE DAY REDUCTION WITH QULIPTA 60 mg (n=216)2
-1.03 WMD from 1.93 baseline

VS

15%
MIGRAINE DAY REDUCTION WITH PLACEBO (n=211)2
-0.29 WMD from 1.88 baseline

LIMITATIONS: The additional endpoints were prespecified, non-ranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

See Day 1 Data

IMPROVEMENT IN FUNCTION

Secondary endpoint: Change from baseline in mean monthly AIM-D PDA scores across 12 weeks

  • QULIPTA 60 mg: 59% improvement (-9.4 points from 15.9 baseline) (n=222; P<0.001)1
  • QULIPTA 30 mg: 51% improvement (-8.6 points from 16.9 baseline) (n=223; P<0.001)1
  • QULIPTA 10 mg: 47% improvement (-7.3 points from 15.5 baseline) (n=214)1*
  • Placebo: 40% improvement (-6.1 points from 15.2 baseline) (n=214)1

*The 10 mg results were not statistically significant.1

Post-hoc analysis: Change from baseline in performance of daily activities at Week 1 as measured by AIM-D PDA

Up arrow

49%
IMPROVEMENT IN FUNCTION WITH QULIPTA 60 mg (n=222)2
-7.74 points from 15.7 baseline

VS

24%
IMPROVEMENT IN FUNCTION WITH PLACEBO (n=214)2
-3.52 points from 14.84 baseline

  • QULIPTA 30 mg: 53% improvement in function (-7.76 points from 14.55 baseline) (n=223)2
  • QULIPTA 10 mg: 42% improvement in function (-5.48 points from 12.92 baseline) (n=214)2

LIMITATIONS: Performance of daily activities at Week 1 as measured by AIM-D PDA was a post-hoc analysis that was not prespecified or adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

AIM-D PDA=Activity Impairment in Migraine-Diary Performance of Daily Activities.

CHRONIC MIGRAINE

Powerful migraine day reductions in chronic migraine

On average, at baseline patients in this study had:

HIGH FREQUENCY
~19 MMD1

PREVENTIVE TREATMENT EXPERIENCE
83% had preventive exposure2

SEVERE DEBILITATION
>15 acute medication use days;
~43 MSQ-RFR score1

MEDICATION OVERUSE
Nearly two-thirds of patients who were studied overused acute medication2

Patients with chronic migraine reclaimed an average of 1 week's worth of migraine-free days per month1

Primary endpoint: Mean MMD reduction across 12 weeks1

Migraine Day Reductions

Down Arrow

QULIPTA 60 mg: -6.9 days from 19.2 baseline MMD
(n=256) (P<0.001)1

Placebo: -5.1 days from 18.9 baseline MMD
(n=246)1

LEARN ABOUT CONTINUOUS CONTROL